文献速递免疫规划卫生政策与健康促进

2023年全球季节性流感疫苗与流感大流行疫苗生产能力

Global production capacity of seasonal and pandemic influenza vaccines in 2023.
PubMed 文献 · Vaccine · 2025-02-18

世界卫生组织通过2023年调查估算全球流感疫苗生产能力,并与既往调查比较。超过80%的产能依赖鸡胚,非洲区域没有流感疫苗生产设施。

要点

  • 超过80%的季节性和大流行疫苗产能依赖鸡胚,非洲区域没有流感疫苗生产设施。

核心结论

  • 流感疫苗产能自2019年以来得以维持,但分布存在显著缺口,尤其在低收入和中低收入国家,非洲区域最为突出。
  • 产能分布失衡可能导致大流行时疫苗可及性不均。
  • 加强本地疫苗生产、促进季节性疫苗接种规划、投资下一代流感疫苗或改良生产平台的研发,对改善大流行防范、维持流感疫苗市场和增强本地应对能力至关重要。

研究设计与样本

  • 世界卫生组织定期调查流感疫苗生产商,以估算总体及按区域、疫苗类型和生产工艺划分的季节性和潜在大流行疫苗生产能力。
  • 本次报告基于2023年调查数据,并与既往调查的估算值进行比较;上一次调查估算值为2019年。

主要发现

  • 超过80%的季节性和大流行疫苗产能依赖鸡胚,灭活流感病毒疫苗构成疫苗供应的主体。
  • 除非洲区域外,所有世界卫生组织区域均有流感疫苗生产设施,但流感疫苗生产集中于高收入和中高收入国家。
  • 获取鸡蛋和其他辅助物资可能阻碍实现最大生产能力。

局限性

  • 实现最大生产能力可能受到获取鸡蛋和其他辅助物资的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vaccination is a critical part of the response to an influenza pandemic. Future influenza pandemics will likely leverage existing production processes and manufacturing facilities for seasonal influenza to make pandemic vaccines. Therefore, pandemic influenza vaccine response is heavily dependent on seasonal influenza vaccine production capacity. METHODS: WHO monitors global vaccine production to inform pandemic preparedness by regularly surveying influenza vaccine manufacturers to estimate both seasonal and potential pandemic vaccine production capacity overall and by region, vaccine type, and manufacturing process. The last survey estimates were for 2019; here, we report updated estimates based on data from the 2023 survey and compare to estimates from previous surveys. RESULTS: Our analysis estimates that annual seasonal influenza vaccine production capacity has remained relatively stable since 2019 at 1.53 billion doses and pandemic vaccine capacity at 4.13 and 8.26 billion doses for moderate and best case scenarios, respectively. Over 80 % of seasonal and pandemic vaccine production capacity relies on embryonated eggs, and inactivated influenza virus vaccines comprise the majority of vaccine supply. There is influenza vaccine manufacturing capacity in all WHO regions, except for the African Region, though influenza vaccine production is concentrated in high and upper-middle income countries. The ability to achieve maximum production capacity could be hindered by access to eggs and other ancillary supplies. CONCLUSIONS: While influenza vaccine production capacity has been sustained since 2019, significant gaps persist in its distribution, especially in low and lower-middle income countries, and most notably in the African region. This imbalance in production could result in unequal access to vaccines in the event of a pandemic. Strengthening local vaccine manufacturing, promoting seasonal vaccination programmes, and investing in research and development of next-generation influenza vaccines or improved production platforms are essential to improve pandemic preparedness, sustain the influenza vaccine market, and enable more robust local responses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Taaffe J, Goldin S, Lambach P, et al. Global production capacity of seasonal and pandemic influenza vaccines in 2023. Vaccine. 2025. PMID: 39970592. doi:10.1016/j.vaccine.2025.126839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。